UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Airway-Associated Complications With and Without Primary Tracheotomy in Oral Squamous Cell Carcinoma Surgery

The Journal of craniofacial surgery, 2023-01, Vol.34 (1), p.279-283

2023

Volltextzugriff (PDF)

Anaesthesia Concepts in Patients with Chronic Progressive External Ophthalmoplegia Undergoing Ophthalmic Surgery—A Retrospective Cohort Analysis

Journal of clinical medicine, 2024-08, Vol.13 (16), p.4710

2024

Volltextzugriff (PDF)

Laryngeal Mask Airway Versus Endotracheal Intubation during Lacrimal Duct Stenosis Surgery in Children-A Retrospective Analysis

Children (Basel), 2024-03, Vol.11 (3), p.320

2024

Volltextzugriff (PDF)

Survival After Ditching in Motorized Aircraft, 1989-2022

Aerospace medicine and human performance, 2024-05, Vol.95 (5), p.254-258

2024

Volltextzugriff (PDF)

Release of Hyaluronan in Aneurysmal Subarachnoid Hemorrhage and Cerebral Vasospasm: A Pilot Study Indicating a Shedding of the Endothelial Glycocalyx

Journal of neurosurgical anesthesiology, 2023-04, Vol.35 (2), p.232-237

2023

Volltextzugriff (PDF)

Volumetric Analysis and Clinical Outcome in 54 Patients with Retrobulbar Hematoma

Journal of oral and maxillofacial surgery, 2021-09, Vol.79 (9), p.1914-1920

2021

Volltextzugriff (PDF)

Retrospective analysis of open bedside tracheotomies in a German tertiary care university hospital

Journal of cranio-maxillo-facial surgery, 2021-02, Vol.49 (2), p.140-145

2021

Volltextzugriff (PDF)

Severe odontogenic deep neck space infections: risk factors for difficult airways and ICU admissions

Oral and maxillofacial surgery, 2019-09, Vol.23 (3), p.331-336

2019

Volltextzugriff (PDF)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3401-3411

2019

Volltextzugriff (PDF)

Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia

Canadian journal of anesthesia, 2019-05, Vol.66 (5), p.546-561

2019

Volltextzugriff (PDF)

Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis

Cardiovascular research, 2015-07, Vol.107 (1), p.32-44

2015

Volltextzugriff (PDF)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Cancers, 2022-01, Vol.14 (3), p.526

2022

Volltextzugriff (PDF)

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.694-694

2023

Volltextzugriff (PDF)

Preoperative exercise induces endothelial progenitor cell mobilisation in patients undergoing major surgery – A prospective randomised controlled clinical proof-of-concept trial

Heliyon, 2022-09, Vol.8 (9), p.e10705-e10705, Article e10705

2022

Volltextzugriff (PDF)

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4133-4133

2022

Volltextzugriff (PDF)

BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3576-3576

2022

Volltextzugriff (PDF)

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3502-3502

2021

Volltextzugriff (PDF)

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

Clinical & translational oncology, 2024-05, Vol.26 (5), p.1268-1272

2024

Volltextzugriff (PDF)

mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3509-3509

2018

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Airway-Associated Complications With and Without Primary Tracheotomy in Oral Squamous Cell Carcinoma Surgery

Anaesthesia Concepts in Patients with Chronic Progressive External Ophthalmoplegia Undergoing Ophthalmic Surgery—A Retrospective Cohort Analysis

Laryngeal Mask Airway Versus Endotracheal Intubation during Lacrimal Duct Stenosis Surgery in Children-A Retrospective Analysis

Survival After Ditching in Motorized Aircraft, 1989-2022

Release of Hyaluronan in Aneurysmal Subarachnoid Hemorrhage and Cerebral Vasospasm: A Pilot Study Indicating a Shedding of the Endothelial Glycocalyx

Volumetric Analysis and Clinical Outcome in 54 Patients with Retrobulbar Hematoma

Retrospective analysis of open bedside tracheotomies in a German tertiary care university hospital

Severe odontogenic deep neck space infections: risk factors for difficult airways and ICU admissions

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia

Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial

Preoperative exercise induces endothelial progenitor cell mobilisation in patients undergoing major surgery – A prospective randomised controlled clinical proof-of-concept trial

Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212)

Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212)

Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212)

Impact of the COVID-19 pandemic on colorectal cancer (CRC) care: Data from 22 German cancer centers (CC) and the Institute of Pathology, Ruhr-University Bochum - the AIO (Working Group for Internal Oncology of the German Cancer Society) CancerCOVID Consortium - AIO-YMO/KRK 520/ass

Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab)

Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial

BRAF-mutant metastatic colorectal cancer: Prognostic and predictive value of primary tumor location—A pooled analysis of the AIO studies FIRE-1, CIOX, XELAVIRI, FIRE-3, and VOLFI

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116)

Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109)

Suchergebnisse filtern